Latest On Roche Holding AG (RHHVF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-03-14 06:01 EST | Dividend | A dividend of $9.6 has been announced on Feb 1, 2024. It will be paid Mar 18, 2024 with an ex-dividend date of Mar 14, 2024. | Neutral |  |
| 2023-05-04 18:40 EST | News | Regeneron stock dips amid decline in Eylea sales despite Q1 beat | N/A | |
| 2023-03-16 05:56 EST | Dividend | A dividend of $9.5 has been announced on Feb 2, 2023. It will be paid Mar 20, 2023 with an ex-dividend date of Mar 16, 2023. | Neutral | |
| 2022-03-17 05:56 EST | Dividend | A dividend of $9.3 has been announced on Feb 3, 2022. It will be paid Mar 21, 2022 with an ex-dividend date of Mar 17, 2022. | Neutral | |
| 2021-03-18 05:58 EST | Dividend | A dividend of $9.1 has been announced on Feb 4, 2021. It will be paid Mar 22, 2021 with an ex-dividend date of Mar 18, 2021. | Neutral | |
| 2021-02-12 16:37 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-06 12:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 22:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 18:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 07:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-30 09:06 EST | News | Roche (RHHBY) Presents At ASCO 2020 - Slideshow | N/A | |
| 2020-05-27 06:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 05:43 EST | News | Roche (RHHBY) Investor Presentation - Slideshow | N/A | |
| 2020-05-06 06:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-26 09:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-25 10:00 EST | News | Roche Holding (RHHBY) Presents At Barclays Global Healthcare Conference - Slideshow | N/A | |
| 2020-04-03 22:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 21:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-19 05:56 EST | Dividend | A dividend of $9 has been announced on Jan 30, 2020. It will be paid Mar 23, 2020 with an ex-dividend date of Mar 19, 2020. | Neutral | |
| 2020-02-28 05:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 00:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 00:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-13 01:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-08 00:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-07 01:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-03 00:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-01 01:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 01:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 01:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-25 00:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-16 01:15 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-22 00:38 EST | Financials | Company financials have been released. | Neutral | |
About Roche Holding AG (RHHVF):
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
General
- Name Roche Holding AG
- Symbol RHHVF
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 101,465
- Last Split Factor100:1
- Last Split Date2001-05-04
- Fiscal Year EndDecember
- Web URLhttp://www.roche.com
View More
Valuation
- Trailing PE 26.84
- Forward PE 15.27
- Price/Sales (Trailing 12 Mt.) 4.69
- Price/Book (Most Recent Quarter) 7.43
- Enterprise Value Revenue 5.01
- Enterprise Value EBITDA 12.67
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 24%
- Return on Assets 15%
- Return on Equity 40%
- Earnings Per Share $12.28
- Revenue Per Share $0
- Gross Profit 44.48 billion
- Quarterly Earnings Growth -6.4%
View More
ESG Rating
Highlights
- Market Capitalization 279.14 billion
- PE Ratio 12.67
- PEG Ratio 3.02
- Book Value Per Share $32.31
View More
Share Statistics
- Shares Outstanding 693.13 million
- Shares Float 719.13 million
- % Held by Insiders <1%
- % Held by Institutions 36.78%
View More
Technicals
- Beta 0.21
- 52 Week High $368.36
- 52 Week Low $273.53
- 50 Day Moving Average 339.08
- 200 Day Moving Average 343.57
View More
Dividends
- Forward Annual Dividend Rate $10.12
- Forward Annual Dividend Yield 2.97%
- Payout Ratio 143%
- Dividend Date 2018-03-19
- ExDividend Date 2021-03-18
- Dividend Per Share $8.38
- Dividend Yield 0%
View More
Roche Holding AG (RHHVF) Dividend Calendar:
RHHVF's last dividend payment was made to shareholders on March 19, 2018.
Roche Holding AG pays out 143% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Roche Holding AG (RHHVF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $4.06 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $3.90 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $4.92 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $16.53 billion | $4.85 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $16.03 billion | $2.91 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $16.22 billion | $2.82 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $15.89 billion | $5.11 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $15.27 billion | $5.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $15.23 billion | $1.89 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $14.86 billion | $1.89 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $15.45 billion | $4.30 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $14.47 billion | $4.46 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $14.47 billion | $1.88 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $14.37 billion | $1.89 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $13.73 billion | $3.32 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $3.18 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | $2.40 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $2.52 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $3.20 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $3.26 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $2.15 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $2.20 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $3.19 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $3.08 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $2.22 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $2.30 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $3.61 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $3.63 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $3.40 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $3.35 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $3.63 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $3.62 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $3.33 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $3.24 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $2.60 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $2.73 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $2.64 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $2.73 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $3.59 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $3.30 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $2.00 | $0.00 |
Roche Holding AG (RHHVF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 3.23 billion |
| Income Before Tax | N/A | N/A | N/A | N/A | 3.23 billion |
| Selling General Administrative | N/A | N/A | N/A | N/A | 3.96 billion |
| Gross Profit | N/A | N/A | N/A | N/A | 11.91 billion |
| Ebit | N/A | N/A | N/A | N/A | 4.65 billion |
| Operating Income | N/A | N/A | N/A | N/A | 4.65 billion |
| Income Tax Expense | 590.5 million | 590.5 million | 858 million | 858 million | 545.45 million |
| Total Revenue | N/A | N/A | N/A | N/A | 16.53 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 4.61 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -1.42 billion |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 2.69 billion |
| Net Income Applicable to Common Shares | 3.11 billion | 3.11 billion | 4.04 billion | 4.04 billion | 2.52 billion |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -70.76 million | -68.64 million | 492.34 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -398 million | -398 million | -3.68 billion | -3.57 billion | -770.17 million |
| Net Borrowings | 365.5 million | 365.5 million | -2.86 billion | -2.78 billion | 392.75 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -3.4 billion | -3.3 billion | -3.88 billion |
| Change to Operating Activities | -2.41 billion | -2.41 billion | 2 billion | 1.94 billion | -1.9 billion |
| Change in Cash | N/A | N/A | 199.38 million | 193.39 million | -506.64 million |
| Total Cash from Operating Activities | 3.53 billion | 3.53 billion | 7.37 billion | 7.15 billion | 4.14 billion |
| Depreciation | N/A | N/A | 1.15 billion | 1.11 billion | 1.06 billion |
| Other Cash Flow from Investing Activities | -141.5 million | -141.5 million | 26.34 million | 25.55 million | 7.15 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -85.5 million | -85.5 million | -268.6 million | -260.52 million | -259.45 million |
| Change to Net Income | 800.5 million | 800.5 million | 1.7 billion | 1.65 billion | 583.25 million |
| Capital Expenditures | N/A | N/A | 1.03 billion | 999.5 million | 770.17 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 46.37 billion | N/A | 45.55 billion | N/A | 48.79 billion |
| Total Stockholder Equity | 36.34 billion | 3.11 billion | 31.51 billion | N/A | 33.83 billion |
| Other Current Liabilities | N/A | N/A | 10.24 billion | N/A | 7.66 billion |
| Total Assets | 86.14 billion | N/A | 80.36 billion | N/A | 85.84 billion |
| Common Stock | N/A | 21.41 billion | 160 million | 160 million | 165.29 million |
| Other Current Assets | 123 million | 36.34 billion | 2.81 billion | N/A | 592.98 million |
| Retained Earnings | 45.57 billion | N/A | 39.82 billion | 39.82 billion | 41.86 billion |
| Other Liabilities | N/A | 10.74 billion | 9.37 billion | 9.37 billion | 9.87 billion |
| Other Assets | N/A | 8.66 billion | 7.91 billion | 7.91 billion | 7.2 billion |
| Cash | 5.73 billion | N/A | 3.77 billion | N/A | 6.28 billion |
| Total Current Liabilities | 25.4 billion | 25.4 billion | 22.46 billion | N/A | 24.92 billion |
| Other Stockholder Equity | N/A | N/A | -8.47 billion | -8.47 billion | -8.2 billion |
| Property, Plant & Equipment | N/A | 23.27 billion | 23.25 billion | 23.25 billion | 24.09 billion |
| Total Current Assets | 32.94 billion | 32.94 billion | 27.7 billion | N/A | 32.29 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 763.43 million |
| Net Tangible Assets | N/A | 15.08 billion | 10.01 billion | 10.01 billion | 12.33 billion |
| Short Term Investments | 6.61 billion | N/A | 2.48 billion | N/A | 3.59 billion |
| Long Term Debt | 10.22 billion | N/A | 12.49 billion | N/A | 13.09 billion |
| Inventory | 7.19 billion | 7.19 billion | 6.79 billion | N/A | 6.26 billion |
| Accounts Payable | 3.32 billion | N/A | 3.04 billion | N/A | 3.5 billion |
Roche Holding AG (RHHVF) Chart:
Roche Holding AG (RHHVF) News:
Below you will find a list of latest news for Roche Holding AG (RHHVF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Roche Holding AG (RHHVF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Roche Holding AG (RHHVF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|